# Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer

> **NCT03129074** · PHASE2 · WITHDRAWN · sponsor: **ASLAN Pharmaceuticals**

## Conditions studied

- Advanced or Metastatic Biliary Tract Cancer

## Interventions

- **DRUG:** Varlitinib
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT03129074
- **Lead sponsor:** ASLAN Pharmaceuticals
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-05
- **Primary completion:** 2020-03
- **Final completion:** 2020-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** sponsor decision
- **Last updated:** 2018-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03129074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03129074, "Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03129074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*